Bayer's $400M Cipro Payout Strangled Market, Consumers Say

Law360, New York (April 2, 2012, 2:55 PM EDT) -- A class of consumers argued before California's highest court last week that Bayer AG's $400 million pay-for-delay patent settlement preventing Barr Pharmaceuticals Inc. from selling its generic version of the antibiotic Cipro preserved a monopoly for Bayer that allowed the company to rake in profits.

In their opening brief before the California Supreme Court on March 27, indirect Cipro purchasers asked the court to reverse the state Court of Appeal's ruling last year holding that Bayer's pay-for-delay settlements with Barr hadn't broken competition laws, saying the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.